Evidence map›Paper›PMID 34322225›Full record

ArticleF1000Research2021

A draft reference assembly of the

Kevin McKernan, Liam T Kane, Seth Crawford, Chen-Shan Chin, Aaron Trippe, Stephen McLaughlin

Open access · goldAbstract read
In one paragraph

Article in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 citations in OpenAlex.

  1. The "dark magic mushroom" co-produces amatoxins and psilocybin.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. ExploringJournal of fungi (Basel, Switzerland) · 2025
    Review
  4. Complete mitochondrial genome ofMitochondrial DNA. Part B, Resources · 2025
    Article
  5. Article
  6. Telomere-to-Telomere Haplotype-Resolved Genomes ofJournal of fungi (Basel, Switzerland) · 2024
    Article
  7. Phylogenomics of the psychoactive mushroom genusProceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. ExploringFrontiers in fungal biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kevin McKernanR&D, Medicinal Genomics, Beverly, Mass, 01915, USA.ORCID 0000-0002-3908-1122
Liam T KaneR&D, Medicinal Genomics, Beverly, Mass, 01915, USA.ORCID 0000-0001-7075-0104
Seth CrawfordR&D, Oregon CBD, Corvallis, Oregon, 97330, USA.
Chen-Shan ChinBioinformatics, DNANexus, Mountain View, CA, 94040, USA.
Aaron TrippeR&D, Oregon CBD, Corvallis, Oregon, 97330, USA.
Stephen McLaughlinR&D, Medicinal Genomics, Beverly, Mass, 01915, USA.
Corvallis Environmental Center · USDNAnexus (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the use of high-fidelity single molecule sequencing to assemble the genome of the psychoactive

Indexed as

AgaricalesPsilocybePsilocybinPsilocybinGenomePsilocybe cubensisPsilocybinSingle molecule sequencing

Identifiers

PMID34322225
PMCPMC8220353
OpenAlexW3152690906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.